Literature DB >> 7618285

Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.

G Harrowe1, C Cheng-Mayer.   

Abstract

A T-cell-line-tropic, syncytium-inducing, sCD4- and serum neutralization-sensitive variant (R3H) of the macrophage-tropic, non-syncytium-inducing, sCD4- and serum neutralization-resistant molecular clone HIV-1SF162 was obtained by passage through the T-cell line HUT 78. Sequence analyses of the V1-V5 regions of envelope gp120 of the variant R3H revealed amino acid substitutions in the V3 (amino acids 307, 312) and V4 (amino acid 390) domains. Site-directed mutagenesis of the HIV-1SF162 genome showed that specific mutations in the V3 loop of this isolate can alter tropism and cytopathicity of the virus, but only moderately affect its sensitivity to sCD4 and serum neutralization. These results show that adaptation to growth in T-cell lines can render a primary-like virus sensitive to sCD4 and serum neutralization. However, the extent of T-cell line tropism does not correlate with the degree of susceptibility to sCD4 and serum neutralization. The latter appears to be dependent on the amino acid compositions of the V3 loop and other regions of envelope gp120, whereas the former is primarily determined by the V3 loop. Our findings further illustrate the importance of the V3 loop in influencing HIV-1 cell tropism and syncytium formation, and the interplay among V3 loop residues in maintaining a structure of the loop that influences biological phenotype of the virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618285     DOI: 10.1006/viro.1995.1367

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 3.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

4.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

7.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

8.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.